# A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Study · id `cardio:ct-nct06066528` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06066528](<https://clinicaltrials.gov/study/NCT06066528>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06066528

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 755 participants.

## Technical summary

Registry record NCT06066528. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-27 (actual); primary completion 2025-12-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 755 participants (enrolled count; ClinicalTrials.gov record NCT06066528, source copy `cardio:ctgov-nct06066528-2026-08-06`, retrieved 2026-10-26)
- Started: 2023-11-27 (actual) (ClinicalTrials.gov record NCT06066528, source copy `cardio:ctgov-nct06066528-2026-08-06`, retrieved 2026-10-26)
- Primary completion: 2025-12-12 (actual) (ClinicalTrials.gov record NCT06066528, source copy `cardio:ctgov-nct06066528-2026-08-06`, retrieved 2026-10-26)
- Completion: 2026-04-01 (actual) (ClinicalTrials.gov record NCT06066528, source copy `cardio:ctgov-nct06066528-2026-08-06`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Canada; China; Czechia; Denmark; Finland; Germany; Greece; Hungary; Japan; Netherlands; New Zealand; Poland; South Korea; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT06066528, source copy `cardio:ctgov-nct06066528-2026-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06066528-2026-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
- Acronym: SYNCHRONIZE™-2
- Condition: Obesity
- Condition: Diabetes Mellitus, Type 2
- Intervention (Combination product): Survodutide
- Intervention (Combination product): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 224f211d88cf6b6a9cd9c10d43a89206d8ac05480b81568944c1348f7f4f5e68
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
